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Abstract: Cigarette smoke contains high
concentrations of oxidants and reactive
oxygen species. The aim of this study was to
evaluate the effect of long-term cigarette
smoking on glutathione (GSH) levels in
bronchoalveolar lavage (BAL) fluid. Nineteen
current cigarette smokers and seven healthy
nonsmoking volunteers were included in the
study. BAL was performed by infusion of five
sequential 20 ml aliquots and each aliquot
was immediately aspirated. The levels of GSH
were determined in BAL fluids. The epithelial
lining fluid volume was calculated by the ratio
of urea concentration in BAL fluid to that in
serum. Lower GSH levels were observed in
the BAL fluid of current smokers than in that
of nonsmokers (8.28 ± 0.78, 12.74 ± 1.09
µM respectively, p<0.01) GSH levels in
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Introduction
Cigarette smoking is a predominant etiologic factor
for chronic obstructive pulmonary disease (COPD) (1).
Tobacco smoke contains high concentrations of oxidants
and reactive oxygen species, present in both the gas phase
and the tar phase. It has been estimated that each puff of
smoke contains 1016 oxidants (2-5). Furthermore,
alveolar macrophages and neutrophils in the lower
respiratory tract of smokers have been found increase by
2-4 times and 10 times respectively (6). These
inflammatory cells release additional oxidants capable of
causing cell injury. Tobacco smoke, therefore, leads to an
increased load of oxidants on the respiratory tract, both
directly by the inhalation of oxidants in the smoke and
indirectly by the activation of inflammatory cells (2, 5).
The lung contains antioxidant defense systems against
oxidants (2, 5, 7-9). Glutathione (GSH), a sulphydrylcontaining tripeptide is abundant in the epithelial lining
fluid (ELF), which covers the respiratory epithelial cells. It
protects the oxidation of the sulphydryl group of some

epithelial lining fluid from smokers were also
significantly lower than those from
nonsmokers (p<0.001). Our data suggest
that chronic smoke exposure causes
decreased GSH levels in the BAL fluid of
current smokers, possibly due to the excess
generation of oxidants and/or impairment of
the synthesis of antioxidants at different
cellular levels. The oxidant and antioxidant
imbalance observed in smokers may be a
factor in the pathogenesis of oxidantmediated damage to respiratory airways and
lungs.
Key Words: Bronchoalveolar lavage, Chronic
obstructive pulmonary disease, Glutathione,
Smoking.

proteins and peroxidation of membrane polyunsaturated
fatty acids (2, 5, 7-10).
There are few studies on the GSH levels in the ELF of
current cigarette smokers. Therefore, the aim of this
study was to determine the effects of long-term smoking
on the local antioxidant defense system in the
bronchoalveolar lavage (BAL) fluid of current smokers,
with a focus on GSH levels.
Materials and Methods
Nineteen current smokers with evidence of COPD (14
male, 5 female) (mean age ± SEM, 50.32 ± 2.71 yr.) and
seven healthy nonsmoking volunteers (1 male, 6 female)
(mean age ± SEM, 44.14 ± 2.84 yr.) were recruited from
the outpatient clinic of the Department of Chest Diseass
in the Hospital of Osmangazi University. Informed
consent was obtained.
Clinical findings and results of physical examinations
were in accordance with the criteria of American Thoracic
Society (ATS) for COPD in current smokers (11). The
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Effect of Etidronate on Urinary Calcium/Creatinin Ratio in Postmenopausal Women: A Prospective, Randomized, Placebo Controlled Study

results of electrocardiogram, urinalysis and hematological
and blood chemistry screening tests were normal. None
of the subjects had respiratory tract infection of acute
exacerbation of COPD for 1 month prior to the study. Of
the 19 current smokers, 13 Chest x-rays revealed
pathological changes due to emphysema in 13 of the 19
current smokers (Small, pendulous heart; low, flat
diaphragms; areas of increased radiolucency). Fourteen of
the 19 subjects consumed more than 20 cigarettes per
day and had an average smoking history of 33.89 ± 3.98
pack-years.
All subjects underwent both routine pulmonary
function testing (Fudac 50 spirometry, Analyzer ST 90
spirometry) and arterial blood gas analysis (Eschweiler
System 2000) prior to BAL procedure. Venous blood
samples were obtained from the subjects for the
determination of urea levels.
BAL was performed with standard techniques.
Subjects were premedicated with atropine and diazepam.
Bronchoscopy was performed through the oral route
(Olympus BF Type 2T 10) under local anesthesia with
10% xylocaine and 0.1% pantocaine. The bronchoscope
was wedged in medial or lateral subsegment of the right
middle lobe and 100 ml sterile saline was instilled in 5
aliquots of 20 ml each. After instillation, each aliquot was
immediately aspirated. The fluid recovered was collected
in polyethylene tubes kept on ice. The recovered fluid was
quantitated and filtered through two single layers of
sterile gauze and centrifuged at 500 rpm for 10 min at
4°C in order to separate the cellular constituents.
Total GSH was measured according to the method of
Beutler (12). The reaction of GSH with 5-5’-dithiobis (2nitrobenzoic acid) was monitored at 412 nm.
Urea concentrations in BAL fluid and in sera were
determined by BM-Hitachi 911 automated analyzer with
the original kits of Boehringer-Mannheim based on the
urease method. The volume of ELF was calculated by the
following formula (13):

statistically significant difference in the PaO2, PaCO2 and
O2 saturation between the two groups.
The mean values of all spirometry parameters are
listed in Table 1. The pulmonary function test parameters
of the current smokers were, of course, significantly
lower than those of nonsmokers, except FEV1 / FVC (%).
Current smokers had a lower proportion of instilled
BAL fluid recovered (48.16 ± 2.86 ml) than did
nonsmokers (53.00 ± 3.94 ml). However, this difference
was not significant statistically. Current smokers had ELF
levels that were even greater (1.48 ± 0.20 ml) than those
observed in the nonsmokers (0.95 ± 0.21 ml) (Table 2).
The concentration of GSH was significantly lower in
the BAL fluid of current smokers than in that of
nonsmokers (8.28 ± 0.78 µM, 12.74 ± 1.09 µM
respectively, p < 0.01).
The concentration of GSH in ELF is shown in Table 2.
The composition of BAL fluid differed significantly
between current smokers and controls, regardless of
whether it was expressed as a concentration in BAL fluid
or compared to ELF levels.
There was a significant inverse correlation between
the number of pack-years and the pulmonary function
test parameters, except FEV1 / FVC (%) (Table 3). There
was also a significant negative correlation between the
ELF volume and the number of pack-years. The volume of
BAL fluid correlated positively with FEV1, FEV1 / FVC (%),
PEF, DLCO and kCO, as shown in Table 3. The
concentration of GSH in BAL fluid correlated positively
with the FEV1, VC and FVC. In contrast, the concentration
of GSH in BAL fluid was inversely correlated with the
number of pack-years (Figure 1).
Table 1.

The results of pulmonary function tests (Predictive value %)
(Mean ± SEM).

Controls

Smokers

97.28 ± 4.48
95.29 ± 6.28
97.57 ± 6.45
103.29 ± 5.3
89.43 ± 7.35
100.71 ± 2.81
104.43 ± 5.57

77.32 ± 3.66*
73.58 ± 3.90*
70.95 ± 4.89*
88.47 ± 4.15
61.47 ± 4.29*
80.88 ± 3.65*
85.14 ± 4.41++

ELF = BAL urea / sera urea X recovered BAL volume
The results are expressed as a mean (SEM). Statistical
analysis was carried out by Student’s t test and p < 0.05
was considered statistically significant. Correlations were
analyzed by the Pearson test.
Results
The group of current smokers was slightly older than
the group of normal subjects, but not significantly so.
Arterial blood gas analysis revealed that there was no
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VC
FVC
FEV1
FEV1 / FVC (%)
PEF
DLCO
kCO

* As compared to controls p < 0.01
As compared to controls p < 0.05

+
+
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Table 2.

Concentrations of antioxidants in BAL fluid (Mean ± SEM).

Recovered Volume (ml)
ELF Volume (ml)
GSH (µM)
ELF GSH (µM)

levels of GSH in BAL fluid than those of normal nonsmoking subjects.

Controls

Smokers

53.00 ± 3.94
0.95 ± 0.21
12.74 ± 1.09
902.43 ± 174.85

48.16 ± 2.86
1.48 ± 0.20
8.28 ± 0.78*
307.84 ± 32.22†

† As compared to controls p < 0.001
* As compared to controls p < 0.01

Discussion
In this study, we found that current smokers have
decreased antioxidant defenses, as reflected by lower

Pack-years

BAL Volume

GSH

–0.543 ++
–––
–0.467 ++
–0.474 ++
–0.471 ++
–0.549 ++
–0.604*
–0.589*
–––

0.693*
0.688*
0.518 ++
–––
–––
0.547 ++
0.519 ++
–––
–––

0.505 ++
–––
–––
0.584*
0.585*
–––
–––
–––
–0.537++

FEV1
FEV1 / FVC (%)
PEF
VC
FVC
DLCO
kCO
ELF Volume
Pack–years

Table 3.

Correlation coefficients (r)
between different parameters.

Figure 1.

Negative correlation between
GSH
concentration
and
cigarette consumption (packyears).

As compared to controls p < 0.01
As compared to controls p < 0.05
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Oxidants in cigarette smoke play an important role in
the injury of the lower respiratory system cells. The
reduction of intracellular antioxidants of lung cells
exposed to oxidants in cigarette smoke have previously
been shown in an in vitro study (5). Moreover, smoking
causes a chronic inflammation in the lower respiratory
tract epithelium (14, 15). Cigarette smoke can activate
alveolar macrophages and the alternate pathway of the
complement, in addition to the induction of
polymorphonuclear leukocyte (PMN) chemotaxis and
activation (4, 16). The activated alveolar macrophages
and PMNs are recruited in the lower respiratory system
of cigarette smokers, and oxidants are also produced by
these activated cells (14, 15, 17).
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GSH is the most abundant tripeptide thiol in cells and
protects the cellular components from the effects of
hydrogen peroxide and other hydroperoxides by
providing reducing equivalents. Recently, high levels of
GSH were shown in ELF (10). Cantin et al. have shown
higher levels of GSH in ELF in smokers with a mean
cigarette consumption of 22 pack-years and a mean age
31 years than in controls (10). Furthermore, smokers n
that study had no abnormal findings in chest radiographic
and spirographic examinations. The discrepancy between
the GSH results of Cantin et al. and those of our study is
possibly due to the higher mean age and cigarette
consumption of smokers in our study (50 years and 33
pack-years respectively). It is generally considered that
airway obstruction and bronchus hyperreactivity are the
most prominent findings of long-term exposure to
cigarette smoke (18). In our study, the smokers had
pathological findings in their chest x-rays and spirometric
examinations, which support the airway obstruction
hypothesis. Moreover, the cigarette consumption period
and pack-years are the most important causitive factors
in pathological changes in airways and lungs (19-22). The
significant negative correlation between GSH levels and
pack-years and the significant positive correlation
between GSH levels and FEV1, FVC and VC in our study is
consistent with this knowledge.
Linden et al. put the smokers into obstructive and
non-obstructive groups with a mean age 55 years and a
mean cigarette consumption of 35 pack-years, and found
slightly lower levels of GSH in the ELF of obstructive
smokers than in non-obstructive smokers (14). The mean
GSH level of current smokers in our study is consistent
with the results of Linden et al., especially in that our
study group had obstructive findings in their chest x-rays
and spirometric examinations. Since Linden and
coworkers had no non-smoker control group in the
mentioned study, we were unable to compare our nonsmoker results with theirs.

We hypothesize that smoking causes a compensatory
increase of ELF GSH levels until pathological changes of
lung and airways arise. However, long-term exposure to
cigarette smoke causes a reduction of GSH levels in ELF
accompanied by pathological changes of respiratory tract.
The decreased levels of GSH in the BAL fluid of smokers
might be due to the consumption of GSH during the
detoxification of oxidants in cigarette smoke. It has been
shown that an increased burden of oxidants consumes the
antioxidants during chemical conjugation (5).
McCusker and Hoidal showed increased antioxidant
enzyme activities in order to compensate the oxidant
stress in alveolar macrophages of smokers (23).
However, this increase was reversible, so the enzyme
activities returned to control levels 4 weeks after smoke
exposure stopped. These observations observations
support our hypothesis that smoking causes a
compensatory increase of antioxidant defenses in the
early period, but that long-term cigarette smoking shifts
the oxidant-antioxidant balance toward decreased
antioxidant defenses in current smokers, particularly those
with pathological changes in their respiratory tracts.
In this regard, the antioxidant systems in the BAL fluid
of young smokers can protect the lungs against oxidant
stress, whereas continued smoking in the elderly may
reduce the compensatory elevation of antioxidants that
cause cellular injury.
Our data suggest that chronic smoke exposure causes
decreased GSH levels in BAL fluid from smokers, possibly
due to the excess generation of oxidants and/or the
impairment of the synthesis of antioxidant enzymes or
proteins at different cellular levels. The oxidantantioxidant imbalance observed in smokers may be a
factor in the pathogenesis of oxidant-mediated damage to
respiratory airways and alveolar structures. Further
studies including young and elderly smokers with
obstructive changes in their lower respiratory tracts are
required to clarify the mechanisms.
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